Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Get Free Report) crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.64 and traded as high as $0.90. Brainstorm Cell Therapeutics shares last traded at $0.90, with a volume of 70,724 shares trading hands.
Brainstorm Cell Therapeutics Price Performance
The stock has a 50 day moving average price of $0.62 and a 200-day moving average price of $0.64. The stock has a market capitalization of $9.93 million, a P/E ratio of -0.27 and a beta of 0.69.
Brainstorm Cell Therapeutics Company Profile
BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) is a clinical‐stage biotechnology company focused on developing autologous cell therapies for the treatment of neurodegenerative diseases. The company’s proprietary platform leverages mesenchymal stem cells (MSCs) that are engineered to secrete neurotrophic and growth factors designed to support neuronal survival and function.
The company’s lead product candidate, NurOwn, is an autologous MSC therapy currently in advanced clinical development for amyotrophic lateral sclerosis (ALS).
See Also
- Five stocks we like better than Brainstorm Cell Therapeutics
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Silver paying 20% dividend. Plus 68% share gains
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
